期刊文献+

非小细胞肺癌预后相关的多因素分析 被引量:4

Analysis of Multivariate Clinicopathological Character Related to Prognosis in Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的:分析非小细胞肺癌的临床病理特点与预后的相关因素。方法:应用SPSS软件回顾分析80例获得随访资料的非小细胞肺癌患者的预后相关因素。结果:(1)TNM分期、Ki-67标记指数以及微血管密度是预后的独立危险因素。(2)耐药基因GST-π和病理类型是预后的相对危险因素。(3)患者年龄、性别、病程长短、肿瘤大小、部位、有无坏死与预后无显著相关。结论:TNM分期是非小细胞肺癌最重要的预后独立指标,其次为Ki-67标记指数、微血管密度,而肿瘤耐药基因GST-π和病理类型则是预后相对指标。 Objective: To evaluate the relationship between clinicopathologic characteristics factors related to prognosis in non-SCLC. Methods:80 casas were analyzed and compared by univariate survival and multivariate analysis. Results: (1) TNM Staging,ratio of Ki-67 positivity and microvessel density were independent prognostic factor in non- SCLC. (2)The type of pathology and positive rates of GST-π were relative prognostic factor in non-SCLC. (3)Age,sex, size of tumor,course and cellular necrosis were not correlated with prognosis in non-SCLC. Conclusion :The TNM Staging is the most critical factor. The next is ratio of Ki-67 positivity and the third is microvessel density, while the type of pathology and positive rates of GST-π are relative prognostic factor in non-small cell lung cancer.
出处 《中国误诊学杂志》 CAS 2008年第17期4033-4034,共2页 Chinese Journal of Misdiagnostics
关键词 肺肿瘤/病理学/遗传学/诊断 非小细胞肺/病理学/遗传学/诊断 肿瘤分期 抗药性 肿瘤/遗传学 预后 人类 Lung Neoplasms/pathology/genetics/diagnosis Carcinoma ,Non-Small-Cell Lung/pathology/genetics/diagnosis Neoplasm Staging Drug Resistance ,Neoplasm/genetics Prognosis Humans
  • 相关文献

参考文献8

  • 1Li L,Yang T.Expression of Cdk4,Cyclin D1 and Rb in exogenous wild type P16 gene transfected bladder cancer cell line[J].Colloids and Surfaces Biointerfaces,2003,30(3):315-322.
  • 2Kamoshida S,Matsuoka H,Shiogama K,et al.Immunohistochemical analysis of thymidylate synthase,p16 (INK4a),cyclin dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy:significance of p16 (INK4a)mediated cellular arrest as an indicator of chemosensitivity to 5fluorouracil[J].Pathol Int,2004,54(5):564-575.
  • 3Tanaka F,Yanagihara K,Otake Y,et al.Prognostic factors in resected pathologic (p-) stage ⅢA-N2,non-small-cell lung cancer[J].Ann Surg Oncol,2004,11(6):612-618.
  • 4Iwasaki A,Kuwahara M,Yoshinaga Y,et al.Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels,as prognostic indicators in NSCLC[J].Eur J Cardiothorac Surg,2004,25(3):443-448.
  • 5Shimizu K,Kubo H,Yamaguchi K,et al.Suppression of VEGFR3 signaling inhibits lymph node metastasis in gastric cancer[J].Cancer Sci,2004,95 (4):328-333.
  • 6陈曦,季天海,杨劲松,张哉根,姚丽青,邓军.咽喉部恶性黑色素瘤微血管密度与预后关系的探讨[J].中华耳鼻咽喉科杂志,2001,36(1):44-46. 被引量:16
  • 7Gonlugur U,Pinarbasi H,Gonlugur TE,et al.The association between polymorphisms in glutathione S-translerase (GSTM1 and GSTT1) and lung cancer outcome[J].Cancer lnvest,2006,24(5):497-501.
  • 8Allen TC,Granville LA,Cagle PT,et al.Expression of glutathione S-transferasepi and glutathione synthase correlates with survival in early stage non-small cell carcinomas of the lung[J].Hum Pathol,2007,38(2):220-227.

二级参考文献8

  • 1Relf M,Cancer Res,1997年,57卷,963页
  • 2刘复生,肿瘤病理学,1997年,1773页
  • 3Hollingsworth H C,Am J Pathol,1995年,147卷,33页
  • 4Weidner N,Am J Pathol,1995年,147卷,9页
  • 5Er Horak,Lancet,1992年,340卷,1120页
  • 6Folkman J,J Natl Cancer Inst,1990年,82卷,4页
  • 7Folkman J,Nature,1989年,339卷,58页
  • 8Srivastave A,Eur J Cancer Clin Oncol,1986年,22卷,1205页

共引文献15

同被引文献21

  • 1黄逸生,吴一龙,杨学宁,杨衿记,廖日强.新辅助化疗对非小细胞肺癌预后影响的Meta分析[J].循证医学,2005,5(3):147-155. 被引量:10
  • 2王瑾,许峰,周清华.肺癌流行病学研究进展[J].中国肺癌杂志,2005,8(5):395-400. 被引量:57
  • 3黄爱梅,张勇.盖诺联合顺铂治疗晚期非小细胞肺癌31例临床分析[J].实用全科医学,2006,4(1):79-79. 被引量:3
  • 4肖湘生,于红,李惠民,刘士远,李成洲,刘靖.肺癌支气管动脉与肺动脉CT血管造影分析[J].中华肿瘤杂志,2006,28(4):302-305. 被引量:53
  • 5李体平.非小细胞肺癌淋巴结转移56例分析[J].中国误诊学杂志,2006,6(18):3598-3598. 被引量:1
  • 6Osaki T, Oyama T, Gu CD, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I nonsmall-cell lung cancer[J].Clin Oncol,2002,20(13):2930-2936.
  • 7Cerfolio R J, Bryant AS, Winokur TS, et al. Repeat FDGPET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer [J]. Ann Thorac Surg, 2004, 78(6): 1903-1909.
  • 8Morero JL, Poleri C, Martin C, et al. Influence of apoptosis and cell cycle regulator proteins on chemolherapy response and survival in stage ⅢA/Ⅲ B NSCLC patients[J]. J Thorac Oncol, 2007, 2(4):293-298.
  • 9Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10): 983-991.
  • 10Vargus SO, Leslie KO, Vacek PM,et al. Estrogen-receptor related protein p29 in primary non-small cell lung carcinoma: pathologyic and prognostic correlations [ J ]. Cancer, 1998,82 ( 8 ) : 1495 -1500.

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部